Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: London
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

Synairgen PLC

+ Add to Watchlist

SNG:LN

33.000 GBp 5.000 17.86%

As of 11:30:00 ET on 03/05/2015.

Snapshot for Synairgen PLC (SNG)

Open: 28.000 Day's Range: 28.000 - 33.000 Volume: 1,745,003
Previous Close: 28.000 52wk Range: 26.500 - 86.000 1-Yr Rtn: -33.33%

Stock Chart for SNG

No chart data available.
  • SNG:LN 33.000
  • 1D
  • 1M
  • 1Y
28.000
Interactive SNG Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for SNG

Current P/E Ratio (ttm) 22.6027
Estimated P/E(12/2015) -
Relative P/E vs. UKX 0.9801
Earnings Per Share (GBP) (ttm) 0.0146
Est. EPS (GBP) (12/2015) -0.0520
Est. PEG Ratio -
Market Cap (M GBP) 30.13
Shares Outstanding (M) 91.32
30 Day Average Volume 380,818
Price/Book (mrq) 5.2034
Price/Sale (ttm) 5.9441
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 09/25/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for SNG

  • Revenue
  • Net Income (M/GBP)
  • Profit Margin (%)

Company Profile & Key Executives for SNG

Synairgen PLC is a drug research company. The Company researches treatments for asthma and chronic obstructive pulmonary disease. Synairgen uses an in vitro cell model of human diseases.

Richard James MarsdenCEO/Managing DirectorJohn Christopher WardFinance Director/Secretary
Phillip MonkChief Scientific Officer
More Company Profile & Key Executives for SNG

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil